All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
DiNardo discusses findings from the long-term follow-up of the VIALE-A trial presented at ASH, including the continued improved overall survival of patients treated with azacitidine plus venetoclax compared with azacitidine alone. Covering topics such as prognostic mutational features and European LeukemiaNet risk groups, DiNardo comments on how use of this combination therapy impacts patients with acute myeloid leukemia in the long term.
Subscribe to get the best content related to AML delivered to your inbox